Logo image of APTO

APTOSE BIOSCIENCES INC (APTO) Stock Fundamental Analysis

NASDAQ:APTO - Nasdaq - CA03835T4081 - Common Stock - Currency: USD

1.71  -1.44 (-45.71%)

After market: 2.16 +0.45 (+26.32%)

Fundamental Rating

1

APTO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of APTO have multiple concerns. APTO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

APTO had negative earnings in the past year.
APTO had a negative operating cash flow in the past year.
In the past 5 years APTO always reported negative net income.
APTO had a negative operating cash flow in each of the past 5 years.
APTO Yearly Net Income VS EBIT VS OCF VS FCFAPTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -327.57%, APTO is doing worse than 95.09% of the companies in the same industry.
Industry RankSector Rank
ROA -327.57%
ROE N/A
ROIC N/A
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APTO Yearly ROA, ROE, ROICAPTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

APTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APTO Yearly Profit, Operating, Gross MarginsAPTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

1

2. Health

2.1 Basic Checks

There is no outstanding debt for APTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APTO Yearly Shares OutstandingAPTO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
APTO Yearly Total Debt VS Total AssetsAPTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -79.84, we must say that APTO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of APTO (-79.84) is worse than 95.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -79.84
ROIC/WACCN/A
WACCN/A
APTO Yearly LT Debt VS Equity VS FCFAPTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

APTO has a Current Ratio of 1.05. This is a normal value and indicates that APTO is financially healthy and should not expect problems in meeting its short term obligations.
APTO has a Current ratio of 1.05. This is amonst the worse of the industry: APTO underperforms 87.89% of its industry peers.
A Quick Ratio of 1.05 indicates that APTO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.05, APTO is doing worse than 86.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.05
APTO Yearly Current Assets VS Current LiabilitesAPTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

1

3. Growth

3.1 Past

APTO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.66%.
EPS 1Y (TTM)-237.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.16% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.43%
EPS Next 2Y38.98%
EPS Next 3Y26.36%
EPS Next 5Y17.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APTO Yearly Revenue VS EstimatesAPTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 100M 200M 300M 400M 500M
APTO Yearly EPS VS EstimatesAPTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100 -200 -300 -400 -500

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APTO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APTO Price Earnings VS Forward Price EarningsAPTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APTO Per share dataAPTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15 -20 -25

4.3 Compensation for Growth

APTO's earnings are expected to grow with 26.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.98%
EPS Next 3Y26.36%

0

5. Dividend

5.1 Amount

APTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

APTOSE BIOSCIENCES INC

NASDAQ:APTO (4/1/2025, 8:17:01 PM)

After market: 2.16 +0.45 (+26.32%)

1.71

-1.44 (-45.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners6.66%
Inst Owner Change0%
Ins Owners1.13%
Ins Owner Change4.24%
Market Cap4.36M
Analysts82.5
Price Target85.85 (4920.47%)
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.9%
Min EPS beat(2)64.27%
Max EPS beat(2)69.52%
EPS beat(4)4
Avg EPS beat(4)37.14%
Min EPS beat(4)3.29%
Max EPS beat(4)69.52%
EPS beat(8)6
Avg EPS beat(8)16.25%
EPS beat(12)9
Avg EPS beat(12)9.71%
EPS beat(16)12
Avg EPS beat(16)10.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.86%
PT rev (3m)2004.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-767.77%
EPS NY rev (1m)-2900%
EPS NY rev (3m)-1657.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26.07
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-14.58
FCFYN/A
OCF(TTM)-14.58
OCFYN/A
SpS0
BVpS-3.58
TBVpS-3.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -327.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 1.05
Altman-Z -79.84
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.76%
Cap/Depr(5y)62.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-237.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.15%
EPS Next Y91.43%
EPS Next 2Y38.98%
EPS Next 3Y26.36%
EPS Next 5Y17.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.1%
EBIT Next 3Y11.61%
EBIT Next 5YN/A
FCF growth 1Y6.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.39%
OCF growth 3YN/A
OCF growth 5YN/A